Tenderwize
Retour à la recherche

Non-exclusive rebate agreement for Eltrombopag

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 33 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Eltrombopag (ATC-Code nach WHO: B02BX05)

46/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

46 / 100

Complexité

58 / 100

Facteurs de risque

Demand is explicitly unknown and depends on patient numbers, prescribing behaviour, and pharmacy stocking behaviour; mi...

Participation documents must be obtained through the DTVP project room, and the notice says submission cannot be made v...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Non-exclusive supply of pharmaceutical products containing Eltrombopag.
  • Conclusion of rebate agreements under § 130a Abs. 8 SGB V in an open-house model.
Afficher le résumé complet

Open-house supply arrangement for non-exclusive pharmaceutical rebate agreements for Eltrombopag (ATC B02BX05) led by AOK PLUS. The procedure is open to all interested pharmaceutical companies that meet the stated participation conditions. No individual negotiations or exclusivity apply, and the purchase volume is unknown and not guaranteed. Participation documents are available via DTVP, but the extracted procurement documents themselves were not provided for analysis.

Risques

Demand is explicitly unknown and depends on patient numbers, prescribing behaviour, and pharmacy stocking behaviour; mi...

Participation documents must be obtained through the DTVP project room, and the notice says submission cannot be made v...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal product.
  • For the offered medicinal product, the company must have its seat in Germany, another EU Member State, or another EEA state, as stated in the notice.

Eligibility

  • Submission of the completed declaration of non-existence of exclusion grounds is required.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive rebate agreement for Eltrombopag

Supply lot for a non-exclusive pharmaceutical rebate agreement under § 130a(8) SGB V for the active substance Eltrombopag (ATC B02BX05). The scope excludes the indication acquired severe aplastic anemia unless the bidder holds valid patent rights or a patent-preserving licence. Open-house model means any eligible pharmaceutical company may join during the participation period; no exclusivity or individual negotiation applies. Place of performance is Dresden, Germany, with performance geography also stated as Saxony and Thuringia in the XML notice.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Sep 2025 - Sep 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Sep 30, 2026

Détails de la procédure

Date de publication
12 Aug 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
529414-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30